Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 14/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246011 | 0.91 | SCD (0.62) | SCDHDAC1PPARDPPARAGRM2 | |
| SCHEMBL245153 | 0.90 | SCD (0.60) | SCDHDAC1ALDH1A1 | |
| SCHEMBL347271 | 0.89 | SCD (0.79) | SCDHDAC1ALDH1A1 | |
| SCHEMBL347630 | 0.87 | SCD (0.79) | SCDHDAC1ALDH1A1 | |
| SCHEMBL245130 | 0.87 | SCD (0.62) | SCDHDAC1PPARDPPARA | |
| SCHEMBL347927 | 0.86 | SCD (0.69) | SCDGRM2 | |
| SCHEMBL242657 | 0.86 | SCD (1.00) | SCDHDAC1GRM2 | |
| SCHEMBL245933 | 0.85 | SCD (0.60) | SCDHDAC1PPARDPPARA | |
| SCHEMBL244691 | 0.85 | SCD (0.62) | SCDALDH1A1 | |
| SCHEMBL347383 | 0.85 | SCD (0.82) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102007123-B | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG | 2014-04-30 | — | — | CN | claimed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | claimed |
| CN-102007123-B | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG | 2014-04-30 | — | — | CN | disclosed |
| US-8318949-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| CN-102007123-A | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG | 2011-04-06 | — | — | CN | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885HDAC1 136/4885TYMS 726/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | SCD 1/4885HDAC1 136/4885TYMS 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.